Cytomegalovirus Infection
Conditions
Interventions
First, anti-allergic medication such as diphenhydramine at a dose of 1mg/kg and antipiretic such as dipyrone or paracetamol will be administered.
After administration of anti-allergy and antipiretic
Biological/vaccine
A11.118.637.555.567.569
Sponsors
Sociedade Beneficente Israelita Brasileira - Hospital Israelita Albert Einstein
Sociedade Beneficente Israelita Brasileira - Hospital Israelita Albert Einstein
Eligibility
Inclusion criteria
Inclusion criteria: Patients of both sexes. Patients who have undergone allogeneic bone marrow transplantation. Patients who have cytomegalovirus infection or reactivation without clinical improvement or CMV copy decline after at least 2 weeks of treatment with standard anti-viral therapy.
Exclusion criteria
Exclusion criteria: Patients who have received ATG, Campath or other immunosuppressive monoclonal antibody in less than 28 days. Patients who have received infusion of donor lymphocytes in less than 28 days. Patients with other uncontrolled infections than cytomegalovirus. Patients with Grade II to IV active graft versus host disease (GVHD). Patients receiving corticosteroid therapy with equivalent or higher doses of prednisone 0.5mg/kg.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Reduction in cytomegalovirus viral load as measured by laboratory tests. | — |
Secondary
| Measure | Time frame |
|---|---|
| Grading of adverse reactions, such as graft versus host disease with annotations in relation to cutaneous rash, diarrhea and liver function. Adverse reactions should also be measured by laboratory tests such as bilirubin, alkaline phosphatase, gamma-GT, TGO and TGP, blood counts with platelet counts, renal function with creatinine, and urea. | — |
Countries
Brazil
Contacts
Public ContactNelson Hamerschlak
Sociedade Beneficente Israelita Brasileira - Hospital Israelita Albert Einstein
Outcome results
None listed